09.05.24
Evotec SE and X-Chem have entered a collaboration agreement focused on accelerating early-stage drug discovery.
X-Chem’s DNA-encoded library (DEL) technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, thereby identifying potential start points with high efficiency and precision.
In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets.
“Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery,” said Karen Lackey, CEO of X-Chem. “This collaboration highlights our commitment to partner with leading research organizations, like Evotec, to make DEL screening services more accessible.”
“We are pleased to collaborate with X-Chem and to leverage their leading DEL platform and capabilities,” said Craig Johnstone, chief operating officer of Evotec. “X-Chem’s expertise in DEL, combined with their advanced data-mining solutions, provides us with access to an additional tool to tackle innovative and difficult biological targets.”
X-Chem’s DNA-encoded library (DEL) technology streamlines hit finding by simultaneously screening up to billions of DNA-tagged compounds, thereby identifying potential start points with high efficiency and precision.
In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets.
“Partnerships to access best-in-class platforms are the way forward to address the complexity in drug discovery,” said Karen Lackey, CEO of X-Chem. “This collaboration highlights our commitment to partner with leading research organizations, like Evotec, to make DEL screening services more accessible.”
“We are pleased to collaborate with X-Chem and to leverage their leading DEL platform and capabilities,” said Craig Johnstone, chief operating officer of Evotec. “X-Chem’s expertise in DEL, combined with their advanced data-mining solutions, provides us with access to an additional tool to tackle innovative and difficult biological targets.”
